We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STLA:NYSEStellantis N.V. Analysis

Data as of 2026-09-09 - not real-time

$5.33

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Stellantis N.V. is bearish at $5.33, with short-term averages lagging the long-term ones. It has lost 7.5% over the past 30 days. Momentum indicators put RSI at 46.2 (neutral) with MACD reading bullish. Price has been bracketed by support at $5.05 and resistance at $5.57.
Valuation screens as undervalued, on a P/E of 4.3 with no clean sector comparison available. Sell-side targets cluster 30.9% above the current quote. Revenue is growing at 13.1% on a -12.1% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 45.2%, a beta of 1.40 and a maximum drawdown of 58.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

・Q2 earnings fell to €0.12 per share, from €0.15 per share last year. ・The automaker also reaffirmed its...Stellantis NV STLA reports strong revenue growth and positive free cash flow, but faces pricing pressure and inventory...Yahoo Finance1monStellantis NV STLA H1 2026 Earnings Call Highlights: Revenue Surges 13% as Cost-Cutting .

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 7.77
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 7.77
  • Analyst targets imply +30.9% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Negative profit margin of -12.1%
  • Analyst targets imply +30.9% versus the current price
  • Negative return on equity of -28.7%

Key Metrics & Analysis

Financial Health

Revenue Growth13.10%
Profit Margin-12.10%
P/E Ratio4.3
ROE-28.69%
ROA-1.13%
Debt/Equity84.39
P/B Ratio0.2
Op. Cash Flow$-5249999872
Free Cash Flow$-3031000064

Technical Analysis

TrendBearish
RSI46.2
Support$5.05
Resistance$5.57
MA 20$5.33
MA 50$5.55
MA 200$7.77
MACDBullish
VolumeDecreasing
Fear & Greed Index92.46

Valuation

Target Price$6.98
Upside/Downside30.94%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.40
Volatility45.23%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.